46 results on '"Hofmann W. -K."'
Search Results
2. Course of colonization by multidrug-resistant organisms after allogeneic hematopoietic cell transplantation
3. Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia
4. Diagnostic Performance of Contrast Enhanced Pulmonary Computed Tomography Angiography for the Detection of Angioinvasive Pulmonary Aspergillosis in Immunocompromised Patients
5. Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients
6. Erratum: Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia
7. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis
8. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)
9. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia
10. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
11. Allogeneic hematopoietic cell transplantation without fluconazole and fluoroquinolone prophylaxis
12. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis
13. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event
14. Myelodysplastische Syndrome
15. MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure
16. Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML)
17. Patients with malignant hematological disorders treated on a palliative care unit: prognostic impact of clinical factors
18. SETBP1 mutation analysis in 944 patients with MDS and AML
19. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase
20. Myelodysplasien
21. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload
22. Analysis of NUP98/NSD1 translocations in adult AML and MDS patients
23. Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations
24. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study
25. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia
26. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation
27. Antileukemic activity of the HSP70 inhibitor pifithrin-μ in acute leukemia
28. BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia
29. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome
30. Combined automated cell and flow cytometric analysis enables recognition of persistent polyclonal B-cell lymphocytosis (PPBL), a study of 25 patients
31. Discovery of epigenetically silenced genes in acute myeloid leukemias
32. Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks
33. Methylation analysis of asparagine synthetase gene in acute lymphoblastic leukemia cells
34. Normalization of coronary blood flow in the infarct-related artery after intracoronary progenitor cell therapy
35. Dlk1 in normal and abnormal hematopoiesis
36. Gene expression profiling of normal hematopoietic progenitor cells under treatment with imatinib in vitro
37. Reply to Aloyz et al
38. Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4
39. Infection of cultured intestinal epithelial cells with severe acute respiratory syndrome coronavirus
40. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes
41. The emergence of a C/EBPα mutation in the clonal evolution of MDS towards secondary AML
42. TGFβ-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34+ cells from healthy donors, but not from patients with AML after MDS
43. Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor α levels
44. Allelotype analysis of the myelodysplastic syndrome
45. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all- trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor
46. Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.